Does the media favor AMZN or VRTX?

In the previous week, Amazon.com had 259 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 275 mentions for Amazon.com and 16 mentions for Vertex Pharmaceuticals. Amazon.com's average media sentiment score of 0.95 beat Vertex Pharmaceuticals' score of 0.83 indicating that Amazon.com is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amazon.com 177 Very Positive mention(s) 56 Positive mention(s) 25 Neutral mention(s) 12 Negative mention(s) 4 Very Negative mention(s) Positive Vertex Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRTX or AXSM?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 18 mentions for Axsome Therapeutics and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.23 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CRSP or VRTX?

In the previous week, CRISPR Therapeutics had 10 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 26 mentions for CRISPR Therapeutics and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat CRISPR Therapeutics' score of 0.47 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Vertex Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRTX or EDIT?

In the previous week, Editas Medicine had 1 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 17 mentions for Editas Medicine and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat Editas Medicine's score of 0.15 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, VRTX or GOOG?

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vertex Pharmaceuticals $12.00B 11.46 $3.95B $15.54 34.92 Alphabet $402.84B 9.01 $132.17B $19.16 15.41

Does the media refer more to VRTX or GOOG?

In the previous week, Alphabet had 150 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 166 mentions for Alphabet and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat Alphabet's score of 0.60 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Alphabet 90 Very Positive mention(s) 9 Positive mention(s) 52 Neutral mention(s) 13 Negative mention(s) 1 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$538.60 -4.02 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$542.36 +3.76 (+0.70%)

As of 05:42 PM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? Vertex Pharmaceuticals's main competitors and comparable companies include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Alphabet (GOOG). Companies are selected based on similarities in market, industry, and size.

How does Vertex Pharmaceuticals compare to Amazon.com?

Amazon.com (NASDAQ:AMZN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Vertex Pharmaceuticals has a net margin of 30.70% compared to Amazon.com's net margin of 16.90%. Vertex Pharmaceuticals' return on equity of 21.98% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amazon.com	16.90%	15.72%	7.79%
Vertex Pharmaceuticals	30.70%	21.98%	15.50%

72.2% of Amazon.com shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 8.9% of Amazon.com shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amazon.com has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Amazon.com is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amazon.com	$716.92B	4.03	$77.67B	$12.37	21.62
Vertex Pharmaceuticals	$12.00B	11.46	$3.95B	$15.54	34.92

In the previous week, Amazon.com had 259 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 275 mentions for Amazon.com and 16 mentions for Vertex Pharmaceuticals. Amazon.com's average media sentiment score of 0.95 beat Vertex Pharmaceuticals' score of 0.83 indicating that Amazon.com is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amazon.com	177 Very Positive mention(s)	56 Positive mention(s)	25 Neutral mention(s)	12 Negative mention(s)	4 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Amazon.com currently has a consensus price target of $321.74, indicating a potential upside of 20.30%. Vertex Pharmaceuticals has a consensus price target of $596.44, indicating a potential upside of 9.92%. Given Amazon.com's stronger consensus rating and higher probable upside, analysts plainly believe Amazon.com is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amazon.com	0 Sell rating(s)	3 Hold rating(s)	55 Buy rating(s)	2 Strong Buy rating(s)	2.98
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Amazon.com beats Vertex Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Vertex Pharmaceuticals presently has a consensus price target of $596.44, indicating a potential upside of 9.92%. Axsome Therapeutics has a consensus price target of $267.58, indicating a potential upside of 85.34%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.96
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Vertex Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 30.70% compared to Axsome Therapeutics' net margin of -18.18%. Vertex Pharmaceuticals' return on equity of 21.98% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	30.70%	21.98%	15.50%
Axsome Therapeutics	-18.18%	-198.73%	-22.03%

In the previous week, Axsome Therapeutics had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 18 mentions for Axsome Therapeutics and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.23 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.46	$3.95B	$15.54	34.92
Axsome Therapeutics	$638.50M	11.89	-$183.17M	-$3.06	N/A

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Vertex Pharmaceuticals has a net margin of 30.70% compared to CRISPR Therapeutics' net margin of -1,812.07%. Vertex Pharmaceuticals' return on equity of 21.98% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
Vertex Pharmaceuticals	30.70%	21.98%	15.50%

In the previous week, CRISPR Therapeutics had 10 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 26 mentions for CRISPR Therapeutics and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat CRISPR Therapeutics' score of 0.47 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Vertex Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics currently has a consensus target price of $72.93, suggesting a potential upside of 71.11%. Vertex Pharmaceuticals has a consensus target price of $596.44, suggesting a potential upside of 9.92%. Given CRISPR Therapeutics' higher probable upside, equities analysts plainly believe CRISPR Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.65
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.96

CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,177.82	-$581.60M	-$4.74	N/A
Vertex Pharmaceuticals	$12.00B	11.46	$3.95B	$15.54	34.92

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Editas Medicine?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Vertex Pharmaceuticals presently has a consensus target price of $596.44, suggesting a potential upside of 9.92%. Editas Medicine has a consensus target price of $5.83, suggesting a potential upside of 172.59%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.96
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.46	$3.95B	$15.54	34.92
Editas Medicine	$40.52M	8.15	-$160.06M	-$0.62	N/A

Vertex Pharmaceuticals has a net margin of 30.70% compared to Editas Medicine's net margin of -144.95%. Vertex Pharmaceuticals' return on equity of 21.98% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	30.70%	21.98%	15.50%
Editas Medicine	-144.95%	-130.43%	-36.45%

In the previous week, Editas Medicine had 1 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 17 mentions for Editas Medicine and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat Editas Medicine's score of 0.15 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Summary

Vertex Pharmaceuticals beats Editas Medicine on 12 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alphabet (NASDAQ:GOOG) are related large-cap companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.3% of Alphabet shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of Alphabet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alphabet has a net margin of 50.03% compared to Vertex Pharmaceuticals' net margin of 30.70%. Alphabet's return on equity of 43.33% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	30.70%	21.98%	15.50%
Alphabet	50.03%	43.33%	29.24%

In the previous week, Alphabet had 150 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 166 mentions for Alphabet and 16 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.83 beat Alphabet's score of 0.60 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Alphabet	90 Very Positive mention(s)	9 Positive mention(s)	52 Neutral mention(s)	13 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Alphabet has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Vertex Pharmaceuticals presently has a consensus target price of $596.44, indicating a potential upside of 9.92%. Alphabet has a consensus target price of $413.38, indicating a potential upside of 39.96%. Given Alphabet's stronger consensus rating and higher possible upside, analysts plainly believe Alphabet is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.96
Alphabet	1 Sell rating(s)	5 Hold rating(s)	35 Buy rating(s)	6 Strong Buy rating(s)	2.98

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.46	$3.95B	$15.54	34.92
Alphabet	$402.84B	9.01	$132.17B	$19.16	15.41

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$136.56B	$4.10B	$7.87B	$12.09B
Dividend Yield	N/A	3.62%	2.46%	4.50%
P/E Ratio	34.66	24.56	34.61	30.52
Price / Sales	11.38	16.88	8.89	5.88
Price / Cash	31.12	26.89	22.23	22.80
Price / Book	6.53	4.14	4.40	3.79
Net Income	$3.95B	-$22.78M	$3.51B	$390.55M
7 Day Performance	-1.55%	-2.71%	-1.49%	-0.29%
1 Month Performance	11.00%	-5.71%	-3.90%	-6.63%
1 Year Performance	23.95%	-0.30%	0.94%	-5.76%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	3.1352 of 5 stars	$538.60 -0.7%	$596.44 +10.7%	+25.0%	$136.56B	$12.00B	34.66	6,400
AMZN Amazon.com	4.8025 of 5 stars	$266.93 +2.9%	$321.74 +20.5%	+9.5%	$2.89T	$797.46B	21.58	1,576,000	Trending News
AXSM Axsome Therapeutics	3.5804 of 5 stars	$133.96 +1.2%	$267.58 +99.7%	+2.5%	$7.05B	$638.50M	N/A	925	Analyst Forecast Analyst Revision
CRSP CRISPR Therapeutics	2.9499 of 5 stars	$50.04 -0.1%	$69.69 +39.3%	-18.3%	$4.85B	$3.51M	N/A	393	Analyst Forecast
EDIT Editas Medicine	2.3198 of 5 stars	$2.75 +7.0%	$5.83 +112.1%	-20.7%	$422.35M	$40.52M	N/A	87	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Is AMZN or VRTX more profitable?

Do insiders and institutionals believe in AMZN or VRTX?

Which has more risk & volatility, AMZN or VRTX?

Which has higher earnings & valuation, AMZN or VRTX?

Does the media favor AMZN or VRTX?

Do analysts recommend AMZN or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Do analysts rate VRTX or AXSM?

Which has more volatility and risk, VRTX or AXSM?

Is VRTX or AXSM more profitable?

Does the media prefer VRTX or AXSM?

Which has higher valuation & earnings, VRTX or AXSM?

Do institutionals & insiders have more ownership in VRTX or AXSM?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Is CRSP or VRTX more profitable?

Does the media favor CRSP or VRTX?

Do analysts rate CRSP or VRTX?

Which has more risk and volatility, CRSP or VRTX?

Which has better earnings and valuation, CRSP or VRTX?

Do institutionals & insiders believe in CRSP or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Do analysts rate VRTX or EDIT?

Do insiders & institutionals hold more shares of VRTX or EDIT?

Which has preferable valuation & earnings, VRTX or EDIT?

Is VRTX or EDIT more profitable?

Does the media refer more to VRTX or EDIT?

Which has more risk and volatility, VRTX or EDIT?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Do institutionals and insiders believe in VRTX or GOOG?

Is VRTX or GOOG more profitable?

Does the media refer more to VRTX or GOOG?

Which has more volatility & risk, VRTX or GOOG?

Do analysts prefer VRTX or GOOG?

Which has higher earnings & valuation, VRTX or GOOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools